One of the explanations of the improved drug efficacy that results from blocking E-selectin in the TME is the fact that uproleselan mobilizes cancer cells (AML and MM) out of the BM, causing anoikis and thus making them more susceptible to chemotherapy [4,23,69,75]. This evidence concerns the gene SELE and Miyoshi myopathy.